JP2002530403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002530403A5 JP2002530403A5 JP2000583898A JP2000583898A JP2002530403A5 JP 2002530403 A5 JP2002530403 A5 JP 2002530403A5 JP 2000583898 A JP2000583898 A JP 2000583898A JP 2000583898 A JP2000583898 A JP 2000583898A JP 2002530403 A5 JP2002530403 A5 JP 2002530403A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- group
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 28
- 125000002947 alkylene group Chemical group 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- -1 nitro, amino Chemical group 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 4
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 3
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010048673 Vitronectin Receptors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- CDVNRGNGAXUMGQ-UHFFFAOYSA-N 2-(1-adamantylmethoxycarbonylamino)-3-[5-[3-oxo-3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)propyl]-2-benzofuran-1-yl]propanoic acid Chemical compound C1C(C2)CC(C3)CC2CC13COC(=O)NC(C(=O)O)CC(=C1C=C2)OC=C1C=C2CCC(=O)NC1=NCCCN1 CDVNRGNGAXUMGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- NOYKASCULDVJNX-UHFFFAOYSA-N C1CNC(=NC1)NC(=O)CCC2=CC3=COC(=C3C=C2)CC(C(=O)O)NS(=O)(=O)NC(=O)OCC4=CC=CC=C4 Chemical compound C1CNC(=NC1)NC(=O)CCC2=CC3=COC(=C3C=C2)CC(C(=O)O)NS(=O)(=O)NC(=O)OCC4=CC=CC=C4 NOYKASCULDVJNX-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- HQNSZNKLTXUUSA-UHFFFAOYSA-N ethyl 3-[5-[3-oxo-3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)propyl]-2-benzofuran-1-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)OCC)CC(=C1C=C2)OC=C1C=C2CCC(=O)NC1=NCCCN1 HQNSZNKLTXUUSA-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/14779 | 1998-11-24 | ||
| FR9814779A FR2786184B1 (fr) | 1998-11-24 | 1998-11-24 | Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| PCT/FR1999/002879 WO2000031070A1 (fr) | 1998-11-24 | 1999-11-23 | Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002530403A JP2002530403A (ja) | 2002-09-17 |
| JP2002530403A5 true JP2002530403A5 (cg-RX-API-DMAC7.html) | 2006-12-14 |
| JP4522586B2 JP4522586B2 (ja) | 2010-08-11 |
Family
ID=9533118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583898A Expired - Lifetime JP4522586B2 (ja) | 1998-11-24 | 1999-11-23 | 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6458801B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1133491B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4522586B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE232859T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69905490T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2192870T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2786184B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000031070A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1176145A1 (en) * | 2000-07-28 | 2002-01-30 | Aventis Pharma Deutschland GmbH | Novel guanidino derivatives as inhibitors of cell adhesion |
| US7078541B2 (en) * | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU675680B2 (en) * | 1992-10-14 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9408577D0 (en) * | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
| ATE227567T1 (de) * | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| GB9522007D0 (en) * | 1995-10-27 | 1996-01-03 | Fujisawa Pharmaceutical Co | New compound |
| US5955495A (en) * | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
| GB9614347D0 (en) * | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US5981514A (en) * | 1998-02-12 | 1999-11-09 | Somberg; John C. | (N-alkyl-N-hydroxymethylamino)alkoxybenzoylbenzofurans and the phosphate esters thereof |
-
1998
- 1998-11-24 FR FR9814779A patent/FR2786184B1/fr not_active Expired - Lifetime
-
1999
- 1999-11-23 DE DE69905490T patent/DE69905490T2/de not_active Expired - Lifetime
- 1999-11-23 US US09/856,542 patent/US6458801B1/en not_active Expired - Lifetime
- 1999-11-23 ES ES99956121T patent/ES2192870T3/es not_active Expired - Lifetime
- 1999-11-23 WO PCT/FR1999/002879 patent/WO2000031070A1/fr not_active Ceased
- 1999-11-23 EP EP99956121A patent/EP1133491B1/fr not_active Expired - Lifetime
- 1999-11-23 JP JP2000583898A patent/JP4522586B2/ja not_active Expired - Lifetime
- 1999-11-23 AT AT99956121T patent/ATE232859T1/de not_active IP Right Cessation
-
2002
- 2002-06-26 US US10/180,253 patent/US6586442B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4596314B2 (ja) | β−アラニン誘導体およびその用途 | |
| RU2576619C2 (ru) | Способ получения пиримидиновых производных | |
| JP2025512474A5 (cg-RX-API-DMAC7.html) | ||
| JP2002536445A5 (cg-RX-API-DMAC7.html) | ||
| JP2009504764A5 (cg-RX-API-DMAC7.html) | ||
| JP2003503385A5 (cg-RX-API-DMAC7.html) | ||
| JP2001515075A5 (cg-RX-API-DMAC7.html) | ||
| RU2001108591A (ru) | Арилпиперазины и их применение в качестве агентов-ингибиторов металлопротеиназ (ммр) | |
| JP2009526865A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| WO2016111347A1 (ja) | 三環性スピロ化合物 | |
| TW201024313A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| CA2805206A1 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
| JP2002030084A5 (cg-RX-API-DMAC7.html) | ||
| JP2020189845A5 (cg-RX-API-DMAC7.html) | ||
| JP2004533464A5 (cg-RX-API-DMAC7.html) | ||
| JP2005511594A5 (cg-RX-API-DMAC7.html) | ||
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ[c]ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| JP2002536438A5 (cg-RX-API-DMAC7.html) | ||
| JPH11501288A (ja) | 金属タンパク質分解酵素阻害剤 | |
| KR20150130392A (ko) | 구아니디노벤조산 에스테르 화합물 | |
| CA2821638C (en) | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
| AU2005202553A1 (en) | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | |
| JPH07504417A (ja) | レトロウイルスプロテアーゼ拮抗薬 | |
| JP2008521934A5 (cg-RX-API-DMAC7.html) |